Researchers at Queen Mary University of London have found that the likelihood of prostate cancer overdiagnosis—the detection of a cancer that would never have been diagnosed during a patient's ...
Michael Platts panicked when he was diagnosed with prostate cancer. Now he wants to help others break through the stigma and ...
The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognized a favorable benefit risk profile for AstraZeneca’s TRUQAP® (capivasertib) in combination with ...
Shares in CRISM Therapeutics rose 19% to 14p on Tuesday after the AIM-quoted drug delivery company reported positive ...
Researchers at Queen Mary University of London have found that the likelihood of prostate cancer overdiagnosis – the detection of a cancer that would never have been diagnosed during a patient’s ...
Researchers at Queen Mary University of London have found that the likelihood of prostate cancer overdiagnosis – the ...
Crism Therapeutics reported positive preclinical results for its Docetaxel-ChemoSeed implant on Tuesday, highlighting ...
Specialists say one of the most powerful aspects of genetic screening is that it often identifies high-risk individuals long ...
US FDA’s ODA committee recommends approval of AstraZeneca’s Truqap for PTEN-deficient metastatic hormone-sensitive prostate cancer: Cambridge, UK Monday, May 4, 2026, 17:00 Hr ...
Investigators proposed criteria to define procedural success after minimally invasive surgical treatments (MISTs) for benign prostatic obstruction (BPO).
Lifestyle factors significantly affect cognitive outcomes in prostate cancer. Discover key statistics and what they mean for ...
Bayer received an FDA Untitled Letter this week for its prostate cancer drug Nubeqa, shortly after it launched a lawsuit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results